NRx Pharma FDA reclassifies ketamine ANDA amendment as minor
NRx Pharmaceuticals said the FDA moved its preservative-free ketamine (NRX-100) ANDA amendment from major to minor and set a GDUFA goal date of Nov. 10, 2026, adding it will not require substantial FDA resources.